Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies (DVAX) has filed an investor presentation defending against Deep Track's proxy contest ahead of its 2025 Annual Meeting. The company highlights its 203% total stockholder return over five years, significantly outperforming vaccine peers (9%) and the S&P Biotechnology Index (-17%). HEPLISAV-B® achieved $268 million in net product revenue in 2024 with 44% U.S. market share. Q1 2025 showed strong growth with HEPLISAV-B® revenue up 36% YoY to $65 million. The company generated over $950 million in revenue during 2020-2022 through pandemic-related business development. Dynavax has completed 85% of its $200 million share repurchase program authorized in November 2024. The company opposes Deep Track's proposal to monetize HEPLISAV-B® and return all cash to shareholders, arguing it would jeopardize long-term growth opportunities.

Dynavax Technologies (DVAX) issued a response to Deep Track Capital's investor presentation and mailed a letter to stockholders ahead of its 2025 Annual Meeting. The company reported strong Q1 2025 results with total revenue of $68.2M (34% YoY growth) and HEPLISAV-B® revenue of $65M (36% YoY growth). HEPLISAV-B® achieved ~43% U.S. market share. The company has completed $172M of its $200M share repurchase program. Dynavax announced new pipeline programs including Pandemic Influenza (Phase 1/2 in Q2 2025) and Lyme Disease (clinical development in 2027). The company urges stockholders to vote "FOR" its four director nominees on the GOLD proxy card, opposing Deep Track's proposal which they argue would harm long-term value. Dynavax has delivered 203% returns over five years, outperforming vaccine peers (9%) and the S&P Biotech Index (-17%).

Dynavax Technologies (DVAX) issued a correction to its stockholder letter regarding value generation metrics, revising from "$1 billion and 104% return" to "over $900 million and 62% return" versus the S&P Biotechnology Index. The company is currently engaged in a proxy battle with Deep Track Capital, defending its strategic direction and urging shareholders to vote for its four director nominees at the June 11, 2025 Annual Meeting.

The company reported strong Q1 2025 results with total revenue of $68.2 million (34% YoY increase), including HEPLISAV-B® revenue of $65 million (36% YoY increase). HEPLISAV-B® achieved ~43% U.S. market share. Dynavax has completed 85% of its $200 million share repurchase program and announced new pipeline programs including Pandemic Influenza and Lyme Disease vaccines.

The company expects 2025 Adjusted EBITDA of at least $75 million and HEPLISAV-B® full-year revenue in the top half of $305-325 million guidance range.

Dynavax (DVAX) reported strong Q1 2025 financial results, with HEPLISAV-B achieving record Q1 net product revenue of $65 million, up 36% year-over-year. The company's U.S. market share increased to 43%. Total revenues reached $68.2 million, a 34% increase from Q1 2024. However, DVAX reported a GAAP net loss of $96.1 million, primarily due to debt refinancing. The company is advancing its pipeline with several programs: a shingles vaccine with Phase 1/2 results expected in Q3 2025, a plague vaccine program funded by the DoD, and new initiatives in pandemic influenza and Lyme disease vaccines. Dynavax maintains its 2025 guidance with HEPLISAV-B revenue expected between $305-325 million. The company has completed 85% of its $200 million share repurchase program and holds $661.3 million in cash and equivalents.

Deep Track Capital, holding approximately 14.53% of Dynavax Technologies (NASDAQ: DVAX) shares, has released an investor presentation titled "The Path to Creating and Preserving Value at Dynavax." As one of DVAX's largest shareholders, Deep Track aims to enhance boardroom objectivity and implement shareholder-aligned capital allocation decisions through their four board nominees. The presentation, available at www.RefocusDVAX.com, outlines their strategy for maximizing shareholder value.

Dynavax Technologies (NASDAQ: DVAX) has released results from a Harris Poll survey revealing significant gaps in public understanding of hepatitis B risks and prevention. The survey found that over 50% of Americans don't know chronic hepatitis B can cause liver disease and half are unaware that anyone can be at risk for the virus. Despite the CDC's universal recommendation for adults over 19 to receive the hepatitis B vaccine, only 20% of participants understand that the vaccine can prevent liver infection. The findings show that 54% of Americans are not concerned about contracting hepatitis B, mainly due to perceived low risk or lack of symptoms. The survey results come as the U.S. Department of Health and Human Services aims to eliminate hepatitis B by 2030, with over 130 million adults currently needing protection. Dynavax will host a LinkedIn Live event on May 27, 2025, featuring experts to discuss the survey findings and education gaps.

Dynavax Technologies (NASDAQ: DVAX) is urging stockholders to vote "FOR" all four company director nominees on the GOLD proxy card at the upcoming 2025 Annual Meeting. The company is facing opposition from Deep Track Capital, which seeks to replace four independent directors.

The current board has overseen impressive performance metrics, including 267% total stockholder returns over five years and record HEPLISAV-B® revenue of $268 million in 2024, capturing 44% U.S. market share. The company projects 2025 revenue of $305-$325 million for HEPLISAV-B®.

Key developments include:

• Executing a $200 million share repurchase program
• Developing a shingles vaccine targeting a $4.4 billion market
• Advancing a plague vaccine with U.S. Department of Defense partnership
• Successfully refinancing Convertible Senior Notes

The board opposes Deep Track's proposals, which include a $400 million share repurchase and royalty financing, arguing these would harm long-term value creation.

Dynavax Technologies (NASDAQ: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.

Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18 and older, and CpG 1018 adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.

Dynavax Technologies (NASDAQ: DVAX) has filed definitive proxy materials for its June 11, 2025 Annual Meeting, urging stockholders to vote for its four director nominees on the GOLD proxy card. The company highlights its strong performance, including 267% total stockholder returns over five years and record HEPLISAV-B® results, with net product revenue growing from $36M in 2020 to $268M in 2024.

The company is executing a balanced strategy focusing on HEPLISAV-B® commercialization and pipeline development, supported by a $200 million share repurchase program, of which $128.8M has been executed in Q1 2025. Dynavax expects 2025 HEPLISAV-B® net product revenue of $305-325M and projects the U.S. hepatitis B vaccine market to reach $900M by 2030.

The proxy battle involves Deep Track Capital, which seeks to replace four independent directors. Dynavax argues that Deep Track's proposals, including increasing share repurchases to $400M and focusing solely on HEPLISAV-B®, would be value-destructive for shareholders.